Subscribe
roschetzkyistockphoto
roschetzky / iStockphoto
16 May 2018Americas

Indivior settles addiction drug dispute with Par

Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.
Americas
Indivior to appeal court verdict over Suboxone Film patents
4 September 2017   Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a US District Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.
Americas
Indivior to appeal court verdict over Suboxone Film patents
4 September 2017   Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a US District Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction.

More on this story

Americas
Indivior obtains court order to block generic Suboxone
18 June 2018   Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.
Americas
Indivior to appeal court verdict over Suboxone Film patents
4 September 2017   Indivior, which specialises in addiction treatment drugs, intends to launch an appeal against a US District Court for the District of Delaware verdict that could lead to rival companies selling a generic version of its Suboxone Film, a drug to treat opioid addiction.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory